Estrella Immunopharma (NASDAQ:ESLA) Upgraded at Wall Street Zen

Estrella Immunopharma (NASDAQ:ESLA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Wednesday. D. Boral Capital decreased their price target on Estrella Immunopharma from $16.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Estrella Immunopharma presently has an average rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Price Performance

ESLA stock opened at $1.12 on Friday. The company has a market capitalization of $42.30 million, a price-to-earnings ratio of -3.29 and a beta of 0.55. Estrella Immunopharma has a 1-year low of $0.73 and a 1-year high of $3.15. The business has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $1.42.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.